527
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma

, , , & ORCID Icon
Pages 1482-1485 | Received 03 Apr 2017, Accepted 30 Aug 2017, Published online: 15 Sep 2017
 

Acknowledgments

This study was sponsored by F. Hoffmann-La Roche Ltd. Medical writing support, under the direction of the authors, was provided by Lucy Carrier and Elizabeth Johnson, Gardiner Caldwell Communications (Macclesfield, UK). Support for third-party writing assistance was provided by F. Hoffmann-La Roche Ltd.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1376740.

Additional information

Funding

This study was sponsored by F. Hoffmann-La Roche Ltd. All authors are employees of F. Hoffmann-La Roche Ltd.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.